Une hépatite inhabituelle chez un patient traité par obinutuzumab et ibrutinib
Stéphane Giorgiutti(Inserm), Luc‐Matthieu Fornecker(Hôpitaux Universitaires de Strasbourg), Marie‐Pierre Ledoux(Hôpitaux Universitaires de Strasbourg), Quentin Maestraggi(Hôpitaux Universitaires de Strasbourg), Raoul Herbrecht(Institut de Cancérologie Strasbourg), Camille Besch(Hôpitaux Universitaires de Strasbourg), Morgane Solis(Inserm), Elise Toussaint(Hôpitaux Universitaires de Strasbourg)
Cited by 0
Related Papers
Revised Definitions of Invasive Fungal Disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group
|Clinical Infectious Diseases|2008|4.9k
Voriconazole versus Amphotericin B for Primary Therapy of Invasive Aspergillosis
|New England Journal of Medicine|2002|3.3k
Practice Guidelines for the Diagnosis and Management of Aspergillosis: 2016 Update by the Infectious Diseases Society of America
|Clinical Infectious Diseases|2016|2.8k
Treatment of Aspergillosis: Clinical Practice Guidelines of the Infectious Diseases Society of America
|Clinical Infectious Diseases|2008|2.7k
Imaging Findings in Acute Invasive Pulmonary Aspergillosis: Clinical Significance of the Halo Sign
|Clinical Infectious Diseases|2007|585